公开(公告)号：WO2023086994A1

公开(公告)日：2023-05-19

申请号：PCT/US2022/079819

申请日：2022-11-14

申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

发明人： OTTERBEIN, Leo E. ,  ALVES DE SOUZA, Rodrigo

IPC分类号： G01N33/72 ,  A61K38/42 ,  C12Q1/28 ,  A61K33/26

摘要： Disclosed herein are methods of assessing cellular or tissue damage in a patient; methods of identifying a patient having sterile inflammation, methods of assessing sterile inflammation in a patient, methods of monitoring a patient undergoing a treatment with a therapeutic agent that causes cellular or tissue toxicity, methods of treating or preventing cellular or tissue damage in a patient in need thereof, methods of treating or preventing sterile inflammation in a patient in need thereof, and related uses and kits.

公开(公告)号：WO2023071365A1

公开(公告)日：2023-05-04

申请号：PCT/CN2022/109934

申请日：2022-08-03

申请人： 含光微纳科技（太仓）有限公司

发明人： 冯澄宇 ,  孙丽亚 ,  吴烨娴

IPC分类号： G01N33/68 ,  G01N33/72 ,  G01N33/92 ,  G01N33/50

摘要： 一种生化项目检测装置，包括：盘片（1）、血浆定量槽（2）、离心囊放置槽（3）、稀释液定量槽（4）、混合槽（5）和混合液过渡槽（6）。生化项目检测装置还包括：生化项目检测孔（14），生化项目检测孔（14）有若干个，且均匀开设在盘片（1）边缘上，通过检测孔进液流道与混合液过渡槽（6）连接，同时，在生化项目检测孔（14）内预埋有不同生化项目检测的冻干试剂。通过对盘片（1）进行离心操作，使血浆样本与稀释液混合且均匀分布于若干个生化项目检测孔（14）内，根据检测生化项目的不同，使混合液与对应的冻干试剂发生反应，进而进行生化项目检测，该检测操作步骤简单、方便，可以达到对单一样本同时进行检测多个血液常规及生化检测项目的技术效果。

公开(公告)号：WO2023023236A1

公开(公告)日：2023-02-23

申请号：PCT/US2022/040732

申请日：2022-08-18

申请人： ALEXION PHARMACEUTICALS, INC.

发明人： COFIELL, Roxanne ,  KIM, Sung-Kwon

IPC分类号： G01N33/50 ,  G01N33/564 ,  G01N33/72

摘要： The present disclosure is directed to methods of identifying a test compounds for treating sickle cell disease (SCD), β-thalassemia (BT), or sickle cell BT. The methods involved contacting a test sample including cells with heme, serum, and a test compound, and measuring a biological phenomena including (1) deposition of a complement factor on the cells in the test sample; or (2) effect(s) of the complement factor deposition of (1) on target effector cells, where an attenuation in the biological phenomena in the test sample compared to the biological phenomena in a reference standard is indicative that the test compound is effective in treating sickle cell disease (SCD), -thalassemia (BT), or sickle cell BT.

公开(公告)号：WO2022250591A1

公开(公告)日：2022-12-01

申请号：PCT/SE2022/050483

申请日：2022-05-18

申请人： DELAVAL HOLDING AB

发明人： CHRISTENSEN, John M ,  DALLERUP RASMUSSEN, Claus ,  TRIER HALD, Jonas

IPC分类号： G01N33/543 ,  G01N33/72

摘要： The present invention relates to a dry stick being a competitive lateral flow stick configured to measure haptoglobin in a raw milk sample, said dry stick comprises a base pad capable of allowing lateral flow of fluid there through, comprising a labelled-control conjugate and a labelled-conjugate diffusibly arranged herein, wherein said labelled-conjugate binds haptoglobin, and wherein a complex is formed between said labelled-conjugate and said haptoglobin when said dry stickis in use. The base pad further comprises a test line comprising immobilised target analyte, wherein said immobilised target analyte binds to said labelled-conjugate when not in said complex; and a control line, which is spaced from said test line,and which comprises control analyte capable of binding to said labelled-control conjugate.

公开(公告)号：WO2022229440A2

公开(公告)日：2022-11-03

申请号：PCT/EP2022/061583

申请日：2022-04-29

申请人： F. HOFFMANN-LA ROCHE AG ,  ROCHE DIAGNOSTICS GMBH ,  ROCHE DIAGNOSTICS OPERATIONS, INC.

发明人： GRUENEWALD, Felix ,  JEGER, Victor Johann Raul ,  KLAMMER, Martin ,  SCHUETZ, Philipp ,  VON HOLTEY, Maria ,  WEBER, Stephen ,  WEGMEYER, Heike ,  WIENHUES-THELEN, Ursula-Henrike

IPC分类号： G01N33/68 ,  G01N33/70 ,  G01N33/72 ,  G01N2333/705 ,  G01N2800/26 ,  G01N2800/50 ,  G01N33/6893 ,  G01N33/728

摘要： The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being sFlt1, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: Cystatin C, IGFBP7, a cardiac Troponin, Creatinine, sTREM1, PCT and Bilirubin, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being sFlt1 and a second biomarker selected from the group consisting of: Cystatin C, IGFBP7, a cardiac Troponin, Creatinine, sTREM1, PCT and Bilirubin, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.

公开(公告)号：WO2022038255A2

公开(公告)日：2022-02-24

申请号：PCT/EP2021/073120

申请日：2021-08-20

申请人： CSL BEHRING AG

发明人： OWCZAREK, Catherine ,  LINDQVIST, Lisa ,  MARTIN, Kirstee ,  GENTINETTA, Thomas

IPC分类号： G01N33/68 ,  G01N33/72 ,  G01N33/6872 ,  G01N33/721

摘要： The present invention relates to the use of a CD91 polypeptide for detection and quantification of a hemopexin:heme complex in a biological sample, to the use of a CD91 polypeptide for separation of a hemopexin:heme complex from a biological sample and to the monitoring of a hemolysis treatment using a CD91 polypeptide.

公开(公告)号：WO2022015131A1

公开(公告)日：2022-01-20

申请号：PCT/MX2020/000015

申请日：2020-07-13

申请人： CENTRO DE INVESTIGACIÓN Y ASISTENCIA EN TECNOLOGÍA Y DISEÑO DEL ESTADO DE JALISCO A.C.

发明人： CAMACHO VILLEGAS, Tanya Amanda ,  PÉREZ PADILLA, Nayeli Areli ,  REZA ESCOBAR, Elia ,  FLORES VALDEZ, Mario Alberto

IPC分类号： C07K16/18 ,  G01N33/72

摘要： Una proteína vNAR aislada, que comprende: un CDR1 que comprende una secuencia de aminoácidos seleccionada del siguiente grupo: SEQ. ID. NO. 1, SEQ. ID. NO. 5, o sus variantes sustancialmente similares a ellas; y un CDR3 que comprende una secuencia de aminoácidos seleccionada del siguiente grupo: SEQ. ID. NO. 2, SEQ. ID. NO. 6, o sus variantes sustancialmente similares a ellas. Una composición que reconoce el blanco o biomarcador de la subunidad beta de la hemoglobina glicada humana, que comprende: al menos, una proteína vNAR de conformidad con la presente invención. Un método ex vivo para el reconocimiento del blanco o biomarcdor de la subunidad beta de la hemoglobina glicada humana, que comprende: proveer una muestra de sangre de un paciente sospechoso de diabetes; contactar la muestra de sangre con la composición de la presente invención; y detectar la presencia de hemoglobina glicada.

公开(公告)号：WO2021204948A1

公开(公告)日：2021-10-14

申请号：PCT/EP2021/059189

申请日：2021-04-08

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ETABLISSEMENT FRANÇAIS DU SANG (EFS) ,  UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE

发明人： BAUDIN-CREUZA, Véronique ,  CHADEBECH, Philippe ,  VASSEUR, Corinne ,  PIRENNE, France

IPC分类号： G01N33/72 ,  G01N33/80

摘要： The present invention relates to a method for determining the quality of haemoglobin (Hb) during the storage period of red blood cell (RBC) units comprising a step of detecting soluble alpha-haemoglobin (α-Hb) pool in RBC lysates and concluding that the presence of α-Hb pool indicates a conservation of quality of Hb during the storage RBCs. Inventors have determined the impact of RBC units aging on the quality of Hb and on the soluble α-Hb pool level in RBCs. For this purpose, 21 RBC units were collected, stored at +4 to 6°C and samples were taken at two different storage times (D3-D8 and D38-D42) to evaluate spectral characteristics of Hb and soluble α-Hb pool in RBCs. Two additional samples were collected from 16 RBC units, at intermediate time points during storage (D13-D17 and D24-D29; n = 16). The α-Hb dosing assay uses the specific character of the interaction between the α-Hb and the AHSP, the α chaperone, to trap the α-Hb present in the RBC lysates of RBC units. They also investigated the effect of a short cryopreservation period at -80°C for 15 days on the α-Hb pool for 4 different RBC units.

公开(公告)号：WO2020193808A1

公开(公告)日：2020-10-01

申请号：PCT/EP2020/058971

申请日：2020-03-30

申请人： DE MARINIS, Yang

发明人： DE MARINIS, Yang

IPC分类号： G01N33/66 ,  G01N33/68 ,  G01N33/72

摘要： With the present disclosure there is detailed use of follistatin as a biomarker for early diagnosis and/or prediction of type 2 diabetes, liver follistatin secretion regulated by GCKR, which use is herein reported. Further, a method of composing a biomarker signature for the early prediction of type 2 diabetes in a human is herein disclosed.

公开(公告)号：WO2020180553A1

公开(公告)日：2020-09-10

申请号：PCT/US2020/019840

申请日：2020-02-26

申请人： SIEMENS HEALTHCARE DIAGNOSTICS INC.

发明人： KAUFFMANN, Aaron

IPC分类号： C12Q1/00 ,  C12Q1/37 ,  G01N33/72

摘要： Non-limiting embodiments of a modified solid reagent zone comprising at least hydrophilic polysaccharide and/or at least one hydrophilic non-polysaccharide polymer for use in the conductance of at least one diagnostic assay, as well as kits and methods of use and production related thereto.